Author

Christine M. Cotter

Observed names: Christine Cotter, Christine M Cotter

Institution: Dana-Farber Cancer Institute

Observed institution: Dana-Farber Cancer Institute

OpenAlex ID: A5077801591

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases

2019 · Rachel A. Freedman, Rebecca S. Gelman, et al. · Journal of Clinical Oncology · 341

TBCRC 022: Phase II trial of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM).

2017 · Rachel A. Freedman, Rebecca Sue Gelman, et al. · Journal of Clinical Oncology · 36

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022

2019 · Rachel A. Freedman, Rebecca S. Gelman, et al. · Clinical Breast Cancer · 29

Abstract PD7-03: Translational Breast Cancer Research Consortium Trial 022: Neratinib and Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases (BCBM)

2023 · Rachel Freedman, Siyang Ren, et al. · Cancer Research · 6

First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.

2015 · David S. Hong, Ignacio Garrido-Laguna, et al. · Journal of Clinical Oncology · 4

Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases

2026 · Thomas Grinda, Hillary M. Heiling, et al. · The Breast

Queensland Health Emergency Department Liaison Project

2010 · Vivien Houston, Cezanne Ballinger, et al. · Parity

Works count: 7

Citation count: 416

H-index: 4

I10-index: 3